Product Pipeline

Overview

Cardiol is leveraging its expertise in drug encapsulation technologies and pharmaceutical cannabinoids to develop proprietary formulations of drugs for commercial development in two important medical markets:

  • Commercializing a line of pharmaceutically-manufactured pure cannabidiol products in 2019 in the growing market for medical cannabinoids.
  • Developing nanoformulations designed to target anti-inflammatory drugs, including cannabidiol, to the heart for the treatment of heart failure.

* Cardiol will advance the most promising nanoformulations for HF into clinical development.